argenx Beheer
Beheer criteriumcontroles 2/4
De CEO argenx is Tim Van Hauwermeiren, benoemd in Apr2008, heeft een ambtstermijn van 16.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.94M, bestaande uit 5.5% salaris en 94.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.023% van de aandelen van het bedrijf, ter waarde € 8.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7.6 jaar.
Belangrijke informatie
Tim Van Hauwermeiren
Algemeen directeur
US$11.9m
Totale compensatie
| Percentage CEO-salaris | 5.5% |
| Dienstverband CEO | 16.6yrs |
| Eigendom CEO | 0.02% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 7.6yrs |
Recente managementupdates
Recent updates
Investor Optimism Abounds argenx SE (EBR:ARGX) But Growth Is Lacking
Nov 03
Is argenx SE (EBR:ARGX) Trading At A 45% Discount?
Aug 24Results: argenx SE Confounded Analyst Expectations With A Surprise Profit
Jul 29argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up
Jun 26argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet
May 01Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects
Apr 11Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report
Mar 24Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report
Mar 05argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate
Feb 23Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely
Dec 18Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher
Jul 28An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued
Jul 17Revenues Tell The Story For argenx SE (EBR:ARGX)
Jun 20argenx (EBR:ARGX) Is Using Debt Safely
May 08We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth
Apr 20Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$40m |
| Jun 30 2024 | n/a | n/a | -US$204m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$12m | US$656k | -US$295m |
| Sep 30 2023 | n/a | n/a | -US$234m |
| Jun 30 2023 | n/a | n/a | -US$397m |
| Mar 31 2023 | n/a | n/a | -US$511m |
| Dec 31 2022 | US$8m | US$639k | -US$710m |
| Sep 30 2022 | n/a | n/a | -US$909m |
| Jun 30 2022 | n/a | n/a | -US$907m |
| Mar 31 2022 | n/a | n/a | -US$595m |
| Dec 31 2021 | US$7m | US$652k | -US$408m |
| Sep 30 2021 | n/a | n/a | -US$373m |
| Jun 30 2021 | n/a | n/a | -US$319m |
| Mar 31 2021 | n/a | n/a | -US$573m |
| Dec 31 2020 | US$9m | US$641k | -US$608m |
| Sep 30 2020 | n/a | n/a | -US$535m |
| Jun 30 2020 | n/a | n/a | -US$359m |
| Mar 31 2020 | n/a | n/a | -US$275m |
| Dec 31 2019 | US$7m | US$589k | -US$181m |
| Sep 30 2019 | n/a | n/a | -US$109m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$47m |
| Dec 31 2018 | US$5m | US$573k | -US$76m |
| Sep 30 2018 | n/a | n/a | -US$56m |
| Jun 30 2018 | n/a | n/a | -US$47m |
| Mar 31 2018 | n/a | n/a | -US$46m |
| Dec 31 2017 | US$4m | US$365k | -US$34m |
Compensatie versus markt: De totale vergoeding ($USD 11.94M ) Tim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Belgian markt ($USD 3.27M ).
Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.
CEO
Tim Van Hauwermeiren (52 yo)
16.6yrs
Tenure
US$11,944,835
Compensatie
Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, serves as Independent Non-Executive Director of Lexeo Therapeutics, Inc since July 2024. He has been Independent Director at iTeos Therapeutics,...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 16.6yrs | US$11.94m | 0.023% € 8.2m | |
| Chief Financial Officer | 3.4yrs | US$4.76m | 0.0049% € 1.7m | |
| Chief Operating Officer | 1.7yrs | US$7.65m | geen gegevens | |
| VP & Global Head of Technical Operations | 2.6yrs | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 1.8yrs | geen gegevens | 0.00085% € 298.9k | |
| VP and Global Head of Corporate Communications & Investor Relations | 2.6yrs | geen gegevens | geen gegevens | |
| General Counsel | 2.8yrs | geen gegevens | 0% € 0 | |
| Vice President of Corporate Development & Strategy | 5.4yrs | geen gegevens | 0.0020% € 714.0k | |
| Global Head of Human Resources | 5.9yrs | geen gegevens | geen gegevens | |
| Global Head of Quality | 4.8yrs | geen gegevens | 0.00050% € 175.9k | |
| Chief Medical Officer | 2.6yrs | geen gegevens | 0.0027% € 949.6k |
2.8yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ARGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 10.3yrs | US$11.94m | 0.023% € 8.2m | |
| Independent Vice-Chairman of the Board | 9.5yrs | US$482.23k | 0.00064% € 225.1k | |
| Independent Chairman of the Board | 10.3yrs | US$660.33k | 0.0023% € 808.9k | |
| Independent Non-Executive Director | 7.6yrs | US$476.82k | 0.00064% € 225.1k | |
| Independent Non-Executive Director | 6.5yrs | US$482.23k | 0.00064% € 225.1k | |
| Independent Non-Executive Director | 8.6yrs | US$471.41k | 0.00064% € 225.1k | |
| Member of Board Advisors | no data | geen gegevens | geen gegevens | |
| Member of Board Advisors | no data | US$622.58k | geen gegevens | |
| Independent Non-Executive Director | 1.8yrs | US$635.65k | 0.00022% € 77.4k | |
| Independent Non-Executive Director | 2.2yrs | US$365.24k | 0.00085% € 298.9k | |
| Member of Board Advisors | 1.7yrs | US$656.08k | 0.0055% € 1.9m | |
| Member of Board Advisors | no data | geen gegevens | geen gegevens |
7.6yrs
Gemiddelde duur
63.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ARGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).